ArticlePreventive medicine reports2026
Trends in diagnosis of amyloid kidney disease in people who inject drugs (PWID).
Article in Preventive medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abstract. Objectives: To characterize temporal trends in amyloid kidney disease among people who inject drugs (PWID) and evaluate associated renal and mortality outcomes. Methods: We conducted a retrospective cohort study using TriNetX data from 2018 to 2025. Trends in amyloid kidney disease with proteinuria or chronic kidney disease (CKD) stage ≥3b were assessed among PWID. Outcomes were compared between PWID with and without renal involvement using propensity score-matched analyses. Results: Age-adjusted incidence of amyloid kidney disease increased from 146 to 238 per 100,000 person-years between 2018 and 2025 (annual percent change 6.8%), while prevalence nearly doubled. Among affected individuals, dialysis incidence increased from 2.04 to 8.83 per 100 person-years. After propensity score matching, renal involvement was associated with higher hazards of death (HR 1.80, 95% CI 1.44,2.25) and dialysis or death (HR 2.54, 95% CI 2.02,3.19). Risks of skin and soft tissue infection and sepsis were similar between groups, while venous thromboembolism or catheter-associated bloodstream infection was modestly increased. Conclusions: Amyloid kidney disease among PWID is increasingly recognized and associated with substantially higher risks of dialysis and death. Earlier recognition of renal involvement may provide opportunities to prevent or slow progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.